Horizon Kinetics Medical ETF

MEDX

Market cap $18.6M

Overview Fund Trends Analyst Outlook Journalist POV

Positive

Neutral

Negative

Sentiment 3-Months

Positive

Neutral 0%

Negative

Zacks Investment Research

ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook

Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.

Zacks Investment Research

ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat

Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.

See News Rankings